Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy.
Teele Kuusk, Yasmin Abu-Ghanem, Faiz Mumtaz...
https://pubmed.ncbi.nlm.nih.gov/33742979/Actively Recruiting
Led by Niels Fristrup · Updated on 2026-09-23
400
Participants Needed
11
Research Sites
156 weeks
Total Duration
Researchers are investigating the role of deferred cytoreductive nephrectomy compared with no surgery in patients with synchronous metastatic renal cell carcinoma mRCC who have intermediate or poor risk features according to the International Metastatic Renal Cell Carcinoma Database Consortium IMDC. The study evaluates the impact of surgery timing after initial treatment with immune checkpoint inhibitors, such as nivolumab combined with ipilimumab, or a tyrosine kinase inhibitor TKI combined with immunotherapy, aiming to improve overall survival in this patient group. Participants receive induction immunotherapy immediately after enrollment, consisting of four series of nivolumab combined with ipilimumab or a TKIIO combination over three months. After this induction, patients are assessed for eligibility for surgery by a multidisciplinary team. Those with three or fewer IMDC risk factors and deemed suitable for surgery are randomized to either deferred nephrectomy followed by maintenance therapy or maintenance therapy alone. Patients not eligible for surgery or with more than three risk factors continue systemic therapy and are reevaluated at six months. Treatment with nivolumab may continue for up to two years or until unacceptable toxicity. During the study, tumor tissue, blood, and stool samples are collected at baseline, three months, and six months for research purposes. Outcomes being measured include overall survival with a minimum follow-up of three years, progression-free survival, response rates, treatment-related side effects, surgical complications, and various biomarker analyses. Participants will be monitored regularly throughout treatment and follow-up, with the study lasting through to the planned completion date in 2031.
CONDITIONS
Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial
N
Niels Fristrup, MD PhD
A
Ane Iversen, MD PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Niels Fristrup
Lead Sponsor
Aarhus University Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 3 months
Participants receive immunotherapy with nivolumab combined with ipilimumab or a TKI/IO combination for approximately 3 months. After this, their eligibility for surgery is assessed by a multidisciplinary team.
Up to 4 treatment sessions
Duration - Up to 2 years of treatment
Participants with suitable risk profiles and eligibility are randomized to either deferred nephrectomy followed by maintenance therapy or maintenance therapy alone. Those not eligible for surgery continue systemic therapy and are re-evaluated at 6 months.
Regular visits as per treatment protocol
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Teele Kuusk, Yasmin Abu-Ghanem, Faiz Mumtaz...
https://pubmed.ncbi.nlm.nih.gov/33742979/Rocco Simone Flammia, Riccardo Campi, Eugenio Bologna...
https://pubmed.ncbi.nlm.nih.gov/41673778/Laura Iisager, Johanne Ahrenfeldt, Frede Donskov...
https://pubmed.ncbi.nlm.nih.gov/38402173/Niels Fristrup
Lead Sponsor
Aarhus University Hospital
Collaborating Sponsor